miR-125在NSCLC EGFR-TKIs耐药前后血清中的表达及其临床意义

发布时间：2018-06-20 11:38

本文选题：miR-125 + 非小细胞肺癌　；参考：《遵义医学院》2017年硕士论文

【摘要】：目的:研究mi R-125在非小细胞肺癌患者EGFR-TKIs耐药前、后血清中的表达,探讨其对EGFR-TKIs疗效的预测价值。方法:通过实时荧光定量RT-PCR法检测36例EGFR-TKIs耐药前、20例耐药后的EGFR突变阳性的晚期肺腺癌患者及13例肺部良性疾病患者的血清标本中mi R-125a-5p及mi R-125b的表达水平。对接受EGFR-TKIs治疗的NSCLC患者进行随访及近期疗效评价。结果:1.EGFR-TKIs耐药前组1.058(0.506~2.313)和耐药后组0.603(0.286~1.154)血清中mi R-125a-5p的表达量均较肺部良性疾病组2.174(1.655~3.317)显著降低(P=0.014,P=0.000)。耐药后组对比耐药前组mi R-125a-5p的表达量显著降低,差异具有统计学意义(P=0.045)。血清中mi R-125b的表达量在耐药前组1.025(0.441~2.957)和耐药后组1.684(1.021~2.532)对比肺部良性疾病组2.122(1.846~3.12)无统计学差异(P=0.074,P=0.456),耐药前与耐药后组比较差异无统计学意义(P=0.259)。在3例耐药前、后的配对血清样本中,mi R-125a-5p和mi R-125b的表达均在耐药后出现下降。2.在EGFR-TKIs耐药患者血清中,mi R-125a-5p和mi R-125b在T790M突变组和未突变组中表达无显著差异(P=0.877,P=0.280)。3.治疗失败组mi R-125a-5p和mi R-125b较治疗缓解组表达均出现低表达,但无统计学差异(P=0.290,P=0.264)。结论:1.血清中mi R-125a-5p的低表达可能与NSCLC的EGFR-TKIs耐药相关,其可作为EGFR-TKIs耐药的潜在标志物,还可作为EGFR-TKIs疗效预测的有效指标。2.EGFR-TKIs耐药患者血清中mi R-125在T790M突变组和未突变组中表达无显著差异。
[Abstract]:Objective: to study the expression of miR-125 in serum of patients with non-small cell lung cancer (NSCLC) before and after EGFR-TKIs resistance, and to explore its predictive value for the efficacy of EGFR-TKIs. Methods: the expression of miR-125a-5p and miR-125b in serum of 36 patients with EGFR-TKIs with EGFR mutation positive and 13 patients with pulmonary benign diseases were detected by real-time quantitative RT-PCR. The patients with NSCLC receiving EGFR-TKIs were followed up and the short-term efficacy was evaluated. Results the expression of miR-125a-5p in the pre- and post-drug resistant group of 1.EGFR-TKIs was significantly lower than that in the benign pulmonary disease group (2.174 ~ 1.655 / 3.317), and the expression of miR-125a-5p in the serum of the former group was significantly lower than that of the benign pulmonary disease group (0.603) and that of the post-drug resistant group (0.603 ~ 0.154) was significantly lower than that of the benign pulmonary disease group. The expression of miR-125a-5p was significantly decreased in the resistant group compared with that in the pre-resistant group, and the difference was statistically significant (P < 0.05). There was no significant difference in the expression of miR-125b between the pre-drug resistant group (1.025) 0.441U 2.957) and the post-resistant group (1.684 ~ 1.021 ~ 2.532) compared with the benign pulmonary disease group (2.122 ~ 1.846 ~ 3.12). There was no significant difference between the pre-drug resistance group and the post-drug resistance group (P = 0.259). The expression of miR-125a-5p and miR-125b in the serum samples of 3 patients before and after drug resistance decreased after drug resistance. There was no significant difference in the expression of mil R-125a-5p and mi R-125b between the T790M mutant group and the non-mutant group in the serum of EGFR-TKIs resistant patients. The expression of mi R-125a-5p and mi R-125b in the failed group was lower than that in the remission group, but there was no statistical difference between the two groups. Conclusion 1. The low expression of miR-125a-5p in serum may be associated with EGFR-TKIs resistance of NSCLC, which can be used as a potential marker of EGFR-TKIs resistance and as an effective index for predicting the efficacy of EGFR-TKIs. 2.The expression of miR-125 in serum of patients with EGFR-TKIs resistance has no significant difference between the T790M mutation group and the non-mutant group.
【学位授予单位】：遵义医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2

【相似文献】